XML 64 R53.htm IDEA: XBRL DOCUMENT v3.19.1
Collaborative Agreements (Details)
1 Months Ended 3 Months Ended 12 Months Ended
Apr. 11, 2018
USD ($)
Dec. 31, 2017
USD ($)
Dec. 29, 2017
Aug. 07, 2015
product
Mar. 31, 2018
USD ($)
Sep. 30, 2015
USD ($)
Apr. 30, 2015
USD ($)
Mar. 31, 2019
USD ($)
Mar. 31, 2018
USD ($)
Dec. 31, 2018
USD ($)
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                    
Revenues               $ 2,829,905 $ 1,529,644  
Deferred grant funding               1,279,005   $ 4,165,848
AstraZeneca                    
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                    
Revenues               2,700,000 1,300,000  
Collaborative Arrangement, Product | ApolloBio                    
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                    
Territory expansion option period     3 years              
Proceeds received in upfront payment         $ 19,400,000          
Upfront payment received         23,000,000     23,000,000   $ 23,000,000
Advisory fees         960,000       960,000  
Additional revenue to be achieved               $ 20,000,000    
Royalty period               10 years    
Period from effective date for termination               1 year    
Number of days written notice before termination               90 days    
Collaborative Arrangement, Product | AstraZeneca                    
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                    
Upfront payment received   $ 27,500,000       $ 27,500,000        
Anticipated development and regulatory event based payment receivable milestones               $ 355,000,000    
Anticipated commercial event based payment receivable milestones               345,000,000    
Number of additional products to be developed | product       2            
Deferred revenue               169,000    
Accounts receivable               2,600,000    
Collaborative Arrangement, Product | Coalition for Epidemic Preparedness Innovations                    
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                    
Collaborative agreement, funding to be received $ 56,000,000                  
Collaborative agreement, period to receive funding for research and development 5 years                  
Funding received for research and development               1,700,000    
Deferred grant funding               424,000    
Collaborative Arrangement, Product | Defense Advanced Research Projects Agency (DARPA)                    
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                    
Funding received for research and development               96,000 $ 376,000  
Base award             $ 19,600,000      
Option award             $ 24,600,000      
Total funding received for research and development               $ 44,200,000    
Foreign Tax Authority | Collaborative Arrangement, Product | ApolloBio                    
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                    
Foreign corporate income taxes reducing upfront payment         2,200,000          
Foreign non-corporate income taxes reducing upfront payment         $ 1,400,000